Compare VanEck Gold Miners ETF (GDX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Smith & Nephew plc — how do they compare? VanEck Gold Miners ETF trades at $89.25 (market cap $25.65B), while Smith & Nephew plc trades at $27.05 (market cap $11.10B). The key difference: VanEck Gold Miners ETF is far larger — about 2.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Smith & Nephew plc for 120 Days on average.
| GDX | SNN | |
|---|---|---|
Market Cap | $25.65B | $11.10B |
Volume | 16,534,046 | 1,051,703 |
52-Week High | $115.84 | $37.17 |
52-Week Low | $68.28 | $26.42 |
Typical Hold Time | 76 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $89.31, up 4.51% over the past 24 hours, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF faces headwinds from rising interest rates pressuring dividend stocks and a recent sell-off in metals. Support levels are clustered between $84 and $86, while resistance sits near $87 to $89. Recent news highlights institutional selling by firms like Allworth Financial and HB Wealth Management, though Ameritas Advisory Services increased its stake.
The outlook for GDX is cautious due to bearish technicals and macroeconomic pressures on gold miners. Opportunities exist if gold prices rebound, but risks include persistent rate hikes and volatility in commodity markets. Investors should weigh the ETF's leverage to gold against operational risks in the mining sector.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
